NIOX Group PLC

Research NIOX Group PLC (NIOX) on Bullrun: market cap GBX 28.87B, P/E 34.3, dividend yield 2.3%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is GBX 28.87B; P/E is 34.3; dividend yield is 2.3%.

Peer valuation comparison

Latest P/E is 34.3x versus a Healthcare sector median of 24.46x (40.2% above).

Latest dividend yield is 2.28% versus a Healthcare sector median of 2.11% (8.1% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025GBP 48.70MGBP 7.00MGBP 13.90M69.2%0.02GBP 19.90MGBP 1.00MGBP 67.60M
FY2024GBP 41.80MGBP 3.70MGBP 16.20M72.2%0.01GBP 10.90MGBP 1.50MGBP 59.50M
FY2023GBP 36.80MGBP 10.70MGBP 11.30M72.0%0.02GBP 19.90MGBP 1.10MGBP 83.80M
FY2022GBP 31.30MGBP 16.10MGBP 6.60M70.9%0.04GBP 19.40MGBP 1.00MGBP 81.90M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-23GBX 28.87B34.32.3%0.02

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.02 GBX, yield 2.3%.

YearDividends/share
FY20251.25 GBP
FY20241 GBP
FY20232.5 GBP

About NIOX Group PLC

NIOX Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis, monitoring, and management of asthma and COPD worldwide. The company offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device, sensors, individual disposable mouthpieces, and breathing handles for the measurement of fractional exhaled nitric oxide (FeNO) level in patients.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is NIOX Group PLC's market cap?

NIOX Group PLC's market capitalization is GBX 28.87B.

What is NIOX Group PLC's P/E ratio?

NIOX Group PLC's price-to-earnings (P/E) ratio is 34.3.

Does NIOX Group PLC pay a dividend?

NIOX Group PLC has a dividend yield of 2.3%.

What does NIOX Group PLC do?

NIOX Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis, monitoring, and management of asthma and COPD worldwide. The company offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device, sensors, individual disposable mouthpieces, and breathing handles for the measurement of fractional exhaled nitric oxide (FeNO) level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022.